# Supernus Pharmaceuticals Inc. (SUPN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Drug Manufacturers - Specialty & Generic. Price $43.53, market value $2.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Supernus Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 3.0×**. Each dollar of revenue is priced at 3.0×.
- **Price / book: 2.5×**. The shares trade at 2.5× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 0.7%** (5-yr avg 5.6%). Free cash flow equals 0.7% of the market value, below its five-year average of 5.6%, so the shares are pricier on cash than usual.

## Profitability
- **Operating margin: -15.7%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -5.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: -3.6%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -7.9%**. Return on all capital, debt included, is -7.9%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -7.6%**. Each dollar of assets produces -7.6% of profit.

## Growth
- **Revenue growth (1 yr): 8.6%** (3-yr 2.5%/yr, 5-yr 6.7%/yr). Revenue grew 8.6% over the last year, against 6.7% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -151.5%**. Earnings per share fell 151.5%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): -26.6%/yr**. Free cash flow has compounded at -26.6% a year over three years.

## Financial health
- **Debt to equity: 0.36**. Debt is 0.36 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Supernus Pharmaceuticals Inc. holds more cash than debt.
- **Current ratio: 1.90** (quick 1.90). Current assets cover the next year's liabilities 1.90 times.
- **Altman Z-score: 5.52**. A Z-score of 5.52 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Supernus Pharmaceuticals Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -4.2%** (YTD -12.4%, 3-mo -2.7%). The shares are down 4.2% over twelve months including dividends.
- **From 52-week high: -27.1%** (2.5% above the low). Trading 27% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 38**. An RSI of 38 is neutral.
- **Beta (1 yr): 0.56** (volatility 36%). Beta of 0.56 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SUPN · Page: https://foliofundamentals.com/stocks/supn

Not investment advice.